Search
forLearn
5 / 801 resultslearn octapeptide-2
learn Actsyl®
learn glutamic acid
learn acetyl cysteine
Research
5 / 485 results
research Evaluation of the palatal wound healing effect of wound dressing carrying GSK-3 antagonist tideglusib on rats
Tideglusib with hydrogel improves wound healing in rats.
research Targeting the Wnt pathways for therapies
Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.
research Isoxazole 9 (ISX9), a small molecule targeting Axin, activates Wnt/β‐catenin signalling and promotes hair regrowth
Isoxazole 9 (ISX9) may help regrow hair by activating certain cell signals.
research ISX9, a small molecule targeting Axin, activates Wnt/β-catenin signaling and promotes hair regrowth
ISX9 helps regrow hair by activating a specific cell signaling pathway.
research Baicalin increases hair follicle development by increasing canonical Wnt/β‑catenin signaling and activating dermal papillar cells in mice
Baicalin helps hair growth by activating specific cell signals and pathways.
Community Join
5 / 1000+ resultscommunity Novel Formulation To Put An End To Hair Loss Once And For All.
A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.
community 48 days of Fin, Min, and Dermaroller
The user has been using finasteride for hair loss for 2-3 years, and added 5% topical minoxidil and daily 1.5mm dermarolling to their routine 50 days ago, which resulted in significant hair growth. The user recommends dermarolling along with minoxidil and finasteride for better results.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.